keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
Published 4 years ago • 431 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
15:51
can triple negative breast cancer spread while on chemo?
-
1:08
neoadjuvant durvalumab shows benefit in triple-negative breast cancer
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
3:50
clinical approach to triple-negative breast cancer
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
1:00
overcoming challenges in treating patients with triple-negative breast cancer
-
1:17
neoadjuvant immunotherapy in tnbc and targeted lnd in breast cancer: 2023 best of breast conference
-
6:16
latest on immunotherapy in triple-negative breast cancer - medpage today
-
1:39
encouraging developments in triple negative breast cancer immunotherapy
-
27:03
triple negative breast cancer: predictive and prognostic biomarkers for neo/adjuvant therapy
-
11:07
metastatic triple negative breast cancer targeted therapy treatment options and potential side effe
-
2:21
how immunotherapy might be effective for triple-negative breast cancer